de los Pinos Elisabet 4

What Happened Elisabet de los Pinos, President and Chief Executive Officer of Aura Biosciences (AURA), was granted two equity awards on 2026-03-02: 166,000 restricted stock units (RSUs) and 249,000 derivative/option-based awards. Both grants show a $0.00 acquisition price (i.e., no cash paid on grant). These are awards, not open-market purchases or sales.

Key Details

• Transaction date: March 2, 2026 (filed March 3, 2026 — timely filing).
• Awards: 166,000 RSUs (@ $0.00) and 249,000 derivative/option-based shares (@ $0.00).
• Reported value/cash paid: $0 at grant (common for RSU/option grants; value realized upon vesting/exercise and any later sale).
• Shares owned after transaction: Not disclosed in the provided filing details.
• Notable footnotes:
  • RSU treatment: Each RSU represents the right to one share; the 166,000 RSUs vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service.
  • Trust holding: A footnote notes shares are held by the Elisabet de los Pinos Revocable Trust (she is a trustee).
  • Derivative/option vesting: The 249,000 option-based award vests 25% on February 1, 2027, with the remainder vesting pro rata over the following 36 months, subject to continued service.
• Filing timeliness: Reported the next day (no late filing flag shown).

Context

• RSUs: These are awards that convert to shares upon vesting; no immediate share delivery or sale occurred at grant. Value to the insider depends on future vesting and the stock price at that time.
• Option-based/derivative award: Vesting schedule disclosed; exercise (and any subsequent sale) would be separate events and reported when they occur.
• Interpretation: This is a standard executive equity compensation grant to align management incentives with shareholder value; it is not an open-market buy or sell and does not by itself indicate immediate insider buying or selling.